8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 14, 2026·SEC
Kiniksa Pharmaceuticals, Ltd.(KNSA)Earnings, Financials & Key Ratios
KNSA•NASDAQ
$58.23
$4.32B mkt cap·77.6× P/E·Price updated May 6, 2026
AboutKiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.Show more
- Revenue$678M+60.1%
- EBITDA$79M+279.4%
- Net Income$59M+236.6%
- EPS (Diluted)0.75+225.0%
- Gross Margin54.63%-36.2%
- EBITDA Margin11.63%+212.0%
- Operating Margin11.4%+205.7%
- Net Margin8.71%+185.3%
- ROE11.73%+219.1%
- ROIC17.13%+252.2%
- Debt/Equity0.02-25.6%
KNSA Key Insights
Kiniksa Pharmaceuticals, Ltd. (KNSA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak 3Y average ROE of 1.8%
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 10.6% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KNSA Price & Volume
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price & volume — 10-year historical chart
Loading chart...
KNSA Growth Metrics
Kiniksa Pharmaceuticals, Ltd. (KNSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years45.45%
TTM56.71%
Profit CAGR
10 Years-
5 Years-
3 Years-31.47%
TTM531.02%
EPS CAGR
10 Years-
5 Years-
3 Years-33.93%
TTM471.43%
Return on Capital
10 Years-45.46%
5 Years-12.03%
3 Years-0.48%
Last Year13.98%
KNSA Recent Earnings
Kiniksa Pharmaceuticals, Ltd. (KNSA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 28, 2026EPS
$0.27
Est $0.18
+50.0%
Revenue
$214M
Est $206M
+4.0%
Q1 2026
Feb 24, 2026EPS
$0.17
Est $0.29
-41.4%
Revenue
$202M
Est $201M
+0.7%
Q4 2025
Oct 28, 2025EPS
$0.23
Est $0.33
-30.3%
Revenue
$181M
Est $197M
-8.2%
Q3 2025
Jul 29, 2025EPS
$0.23
Est $0.18
+27.8%
Revenue
$157M
Est $166M
-5.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.27vs $0.18+50.0% | $214Mvs $206M+4.0% |
| Q1 2026 | Feb 24, 2026 | $0.17vs $0.29-41.4% | $202Mvs $201M+0.7% |
| Q4 2025 | Oct 28, 2025 | $0.23vs $0.33-30.3% | $181Mvs $197M-8.2% |
| Q3 2025 | Jul 29, 2025 | $0.23vs $0.18+27.8% | $157Mvs $166M-5.8% |
Based on last 12 quarters of dataView full earnings history →
KNSA Peer Comparison
Kiniksa Pharmaceuticals, Ltd. (KNSA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARDX | 1.75B | 7.13 | -27.42 | 22.09% | -13.58% | -38.11% | 1.27 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 CABA | 424.39M | 4.15 | -2.53 | -121.73% | 0.24 | |||
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 AMRN | 301.6M | 14.50 | -8.06 | -6.55% | -15.64% | -7.34% | 2.24% | 0.03 |
 INVA | 1.69B | 22.65 | 6.86 | 18.52% | 65.38% | 23.12% | 11.58% |
Compare KNSA vs Peers
Kiniksa Pharmaceuticals, Ltd. (KNSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KNSA Income Statement
Kiniksa Pharmaceuticals, Ltd. (KNSA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M | 754.04M |
| Revenue Growth % | - | - | - | - | - | 471.24% | 22.74% | 56.61% | 60.09% | 56.71% |
| Cost of Goods Sold | 28K | 286K | 3.28M | 3.81M | 9.1M | 22.89M | 56.52M | 60.91M | 307.41M | 245.71M |
| COGS % of Revenue | - | - | - | - | 23.61% | 10.4% | 20.91% | 14.39% | 45.37% | - |
| Gross Profit | -28K▲ 0% | -286K▼ 921.4% | -3.28M▼ 1046.5% | -3.81M▼ 16.0% | 29.44M▲ 873.8% | 197.28M▲ 570.0% | 213.74M▲ 8.3% | 362.33M▲ 69.5% | 370.15M▲ 2.2% | 294.06M▲ 0% |
| Gross Margin % | - | - | - | - | 76.39% | 89.6% | 79.09% | 85.61% | 54.63% | 39% |
| Gross Profit Growth % | -27.27% | -921.43% | -1046.5% | -16.04% | 873.82% | 570.03% | 8.34% | 69.52% | 2.16% | - |
| Operating Expenses | 65.4M | 108.16M | 166.68M | 153.56M | 186.08M | 187.51M | 238.93M | 407.94M | 292.93M | 415.12M |
| OpEx % of Revenue | - | - | - | - | 482.77% | 85.16% | 88.41% | 96.39% | 43.23% | - |
| Selling, General & Admin | 9.04M | 21.56M | 33.75M | 43.92M | 85.95M | 97.95M | 129.43M | 168.01M | 196.27M | 213.89M |
| SG&A % of Revenue | - | - | - | - | 222.99% | 44.49% | 47.89% | 39.7% | 28.97% | - |
| Research & Development | 56.36M | 86.6M | 132.93M | 109.64M | 99.3M | 65.49M | 76.1M | 111.62M | 96.85M | 105M |
| R&D % of Revenue | - | - | - | - | 257.62% | 29.74% | 28.16% | 26.37% | 14.29% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 835K | 24.07M | 33.41M | 128.31M | 0 | 1000K |
| Operating Income | -65.4M▲ 0% | -108.16M▼ 65.4% | -169.96M▼ 57.1% | -157.36M▲ 7.4% | -156.64M▲ 0.5% | 9.77M▲ 106.2% | -25.2M▼ 357.8% | -45.62M▼ 81.0% | 77.22M▲ 269.3% | 93.22M▲ 0% |
| Operating Margin % | - | - | - | - | -406.38% | 4.44% | -9.32% | -10.78% | 11.4% | 12.36% |
| Operating Income Growth % | -172.48% | -65.38% | -57.14% | 7.41% | 0.46% | 106.24% | -357.81% | -81.04% | 269.28% | - |
| EBITDA | -65.37M | -107.87M | -166.68M | -153.56M | -154.28M | 12.18M | -22.86M | -43.92M | 78.78M | 94.42M |
| EBITDA Margin % | - | - | - | - | -400.27% | 5.53% | -8.46% | -10.38% | 11.63% | 12.52% |
| EBITDA Growth % | -172.61% | -65.02% | -54.52% | 7.87% | -0.47% | 107.89% | -287.72% | -92.17% | 279.36% | 763.66% |
| D&A (Non-Cash Add-back) | 28K | 286K | 3.28M | 3.81M | 2.35M | 2.4M | 2.34M | 1.7M | 1.55M | 1.21M |
| EBIT | -65.4M | -108.16M | -163.91M | -156.23M | -156.64M | 9.77M | -25.2M | -45.62M | 88.87M | 70.59M |
| Net Interest Income | 0 | 0 | 6.05M | 1.13M | 97K | 1.25M | 8.54M | 9.46M | 0 | 5.43M |
| Interest Income | 529K | 4.72M | 6.05M | 1.13M | 97K | 1.25M | 8.54M | 9.46M | 0 | 5.43M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 529K | 4.72M | 6.05M | 1.13M | 97K | 1.25M | 8.54M | 9.46M | 11.65M | 12.77M |
| Pretax Income | -64.87M▲ 0% | -103.44M▼ 59.5% | -163.91M▼ 58.5% | -156.23M▲ 4.7% | -156.54M▼ 0.2% | 11.03M▲ 107.0% | -16.65M▼ 251.0% | -36.15M▼ 117.1% | 88.87M▲ 345.8% | 105.98M▲ 0% |
| Pretax Margin % | - | - | - | - | -406.13% | 5.01% | -6.16% | -8.54% | 13.12% | 14.06% |
| Income Tax | 2K | -214K | -2.05M | 5.15M | 1.39M | -172.34M | -30.74M | 7.04M | 29.86M | 12.75M |
| Effective Tax Rate % | -0% | 0.21% | 1.25% | -3.3% | -0.88% | -1563.01% | 184.58% | -19.48% | 33.6% | 12.03% |
| Net Income | -64.87M▲ 0% | -103.23M▼ 59.1% | -161.87M▼ 56.8% | -161.38M▲ 0.3% | -157.92M▲ 2.1% | 183.36M▲ 216.1% | 14.08M▼ 92.3% | -43.19M▼ 406.7% | 59.01M▲ 236.6% | 73.06M▲ 0% |
| Net Margin % | - | - | - | - | -409.72% | 83.28% | 5.21% | -10.21% | 8.71% | 9.69% |
| Net Income Growth % | -170.61% | -59.12% | -56.81% | 0.3% | 2.14% | 216.11% | -92.32% | -406.68% | 236.61% | 531.02% |
| Net Income (Continuing) | -64.87M | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M | 59.01M | 73.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.00▲ 0% | -3.49▼ 74.5% | -2.99▲ 14.3% | -2.61▲ 12.7% | -2.30▲ 11.9% | 2.60▲ 213.0% | 0.20▼ 92.3% | -0.60▼ 400.0% | 0.75▲ 225.0% | 0.89▲ 0% |
| EPS Growth % | -170.27% | -74.5% | 14.33% | 12.71% | 11.88% | 213.04% | -92.31% | -400% | 225% | 471.43% |
| EPS (Basic) | -2.00 | -3.49 | -2.99 | -2.61 | -2.30 | 2.64 | 0.20 | -0.60 | 0.80 | - |
| Diluted Shares Outstanding | 32.47M | 29.55M | 54.05M | 61.84M | 68.58M | 70.42M | 71.92M | 71.42M | 78.98M | 82.41M |
| Basic Shares Outstanding | 32.47M | 29.55M | 54.05M | 61.84M | 68.58M | 69.38M | 70.06M | 71.42M | 74.2M | 76.52M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KNSA Balance Sheet
Kiniksa Pharmaceuticals, Ltd. (KNSA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 47.1M | 313.75M | 241.63M | 333.25M | 196.45M | 243.06M | 276.3M | 331.8M | 527.18M | 594.17M |
| Cash & Short-Term Investments | 45.55M | 307.3M | 233.38M | 323.48M | 182.2M | 190.61M | 206.37M | 243.63M | 414.07M | 468.09M |
| Cash Only | 45.55M | 307.3M | 46.93M | 114.04M | 122.47M | 122.72M | 107.95M | 183.58M | 165.6M | 189.95M |
| Short-Term Investments | 0 | 0 | 186.45M | 209.44M | 59.73M | 67.89M | 98.42M | 60.05M | 248.48M | 278.14M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 3.98M | 20.32M | 21.27M | 41.72M | 15.59M | 0 |
| Days Sales Outstanding | - | - | - | - | 37.74 | 33.68 | 28.72 | 35.98 | 8.4 | 12.01 |
| Inventory | 0 | 0 | 0 | 0 | 3.67M | 21.6M | 31.12M | 26.36M | 54.9M | 0 |
| Days Inventory Outstanding | - | - | - | - | 147.4 | 344.34 | 200.97 | 157.98 | 65.18 | 53.65 |
| Other Current Assets | 105K | 6.45M | 0 | 210K | 0 | 10.54M | 17.54M | 20.08M | 42.61M | 126.08M |
| Total Non-Current Assets | 388K | 8.21M | 12.91M | 16.21M | 36.35M | 216.61M | 250.03M | 248.75M | 236.46M | 231.11M |
| Property, Plant & Equipment | 125K | 6.36M | 8.32M | 10.62M | 8.38M | 7.04M | 12.66M | 11.04M | 11.75M | 0 |
| Fixed Asset Turnover | - | - | - | - | 4.60x | 31.26x | 21.34x | 38.34x | 57.67x | 86.53x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 19.25M | 18.25M | 17.25M | 16.25M | 15.25M | 15M |
| Long-Term Investments | 0 | 210K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 25K | 643K | 210K | 5.59M | 8.72M | 5.82M | 827K | 10.31M | 11.31M | 243.9M |
| Total Assets | 47.49M▲ 0% | 321.96M▲ 577.9% | 254.53M▼ 20.9% | 349.46M▲ 37.3% | 232.8M▼ 33.4% | 459.67M▲ 97.5% | 526.32M▲ 14.5% | 580.55M▲ 10.3% | 763.63M▲ 31.5% | 825.28M▲ 0% |
| Asset Turnover | - | - | - | - | 0.17x | 0.48x | 0.51x | 0.73x | 0.89x | 1.02x |
| Asset Growth % | -15.89% | 577.94% | -20.94% | 37.3% | -33.38% | 97.45% | 14.5% | 10.3% | 31.54% | 119.4% |
| Total Current Liabilities | 17.43M | 42.55M | 27.83M | 31.85M | 44.82M | 47.07M | 63.67M | 100.62M | 139.18M | 156.61M |
| Accounts Payable | 1.22M | 10.92M | 5.69M | 503K | 1.87M | 7.9M | 8.25M | 2.04M | 2.03M | 0 |
| Days Payables Outstanding | 15.88K | 13.93K | 633.71 | 48.25 | 74.93 | 125.93 | 53.25 | 12.22 | 2.41 | 6.36 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.99M | 3.17M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 307K | 0 | 31.81M | 63.62M |
| Other Current Liabilities | 14.64M | 25.96M | 7.11M | 7.74M | 1.54M | 16.97M | 36.91M | 96.59M | 102.36M | 153.44M |
| Current Ratio | 2.70x | 7.37x | 8.68x | 10.46x | 4.38x | 5.16x | 4.34x | 3.30x | 3.79x | 3.79x |
| Quick Ratio | 2.70x | 7.37x | 8.68x | 10.46x | 4.30x | 4.71x | 3.85x | 3.04x | 3.39x | 3.39x |
| Cash Conversion Cycle | - | - | - | - | 110.22 | 252.09 | 176.44 | 181.75 | 71.17 | 59.3 |
| Total Non-Current Liabilities | 119.77M | 144K | 1.28M | 5.68M | 2.94M | 16.46M | 23.82M | 41.5M | 56.84M | 62.98M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.51M | 5.86M |
| Capital Lease Obligations | 0 | 0 | 955K | 4.88M | 2.67M | 2.62M | 10.01M | 7.86M | 0 | 14.27M |
| Deferred Tax Liabilities | 0 | 1.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 119.77M | 144K | 326K | 805K | 270K | 1.84M | 1.86M | 1.82M | 50.33M | 131.25M |
| Total Liabilities | 137.2M | 42.7M | 29.11M | 37.53M | 47.76M | 63.52M | 87.48M | 142.12M | 196.03M | 219.59M |
| Total Debt | 0 | 0 | 2.65M | 6.99M | 6.05M | 5.92M | 12.26M | 9.86M | 9.5M | 9.03M |
| Net Debt | -45.55M | -307.3M | -44.28M | -107.05M | -116.42M | -116.8M | -95.7M | -173.73M | -156.1M | -180.93M |
| Debt / Equity | - | - | 0.01x | 0.02x | 0.03x | 0.01x | 0.03x | 0.02x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | 0.49x | - | - | 0.12x | 0.10x |
| Net Debt / EBITDA | - | - | - | - | - | -9.59x | - | - | -1.98x | -1.98x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -89.71M▲ 0% | -194.22M▼ 116.5% | 225.42M▲ 216.1% | 311.94M▲ 38.4% | 185.04M▼ 40.7% | 396.15M▲ 114.1% | 438.84M▲ 10.8% | 438.44M▼ 0.1% | 567.61M▲ 29.5% | 605.69M▲ 0% |
| Equity Growth % | -248.62% | -116.51% | 216.06% | 38.38% | -40.68% | 114.09% | 10.78% | -0.09% | 29.46% | 98.14% |
| Book Value per Share | -2.76 | -6.57 | 4.17 | 5.04 | 2.70 | 5.63 | 6.10 | 6.14 | 7.19 | 7.35 |
| Total Shareholders' Equity | -89.71M | -194.22M | 225.42M | 311.94M | 185.04M | 396.15M | 438.84M | 438.44M | 567.61M | 605.69M |
| Common Stock | 1K | 13K | 15K | 18K | 18K | 19K | 20K | 20K | 21K | 21K |
| Retained Earnings | -91M | -194.22M | -356.09M | -517.47M | -675.4M | -492.03M | -477.95M | -521.14M | -462.14M | -439.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -52K | -4K | 33K | -34K | -66K | 44K | 6K | -163K | -25K | -665K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KNSA Cash Flow Statement
Kiniksa Pharmaceuticals, Ltd. (KNSA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -50.22M | -81.01M | -158.37M | -136.53M | -126.3M | 5.81M | 13.3M | 25.69M | 25.69M | 25.69M |
| Operating CF Margin % | - | - | - | - | -327.67% | 2.64% | 4.92% | 6.07% | 3.79% | - |
| Operating CF Growth % | -129.66% | -61.32% | -95.49% | 13.79% | 7.5% | 104.6% | 129.05% | 93.14% | 0% | 2361.66% |
| Net Income | -64.87M | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M | -43.19M | 73.06M |
| Depreciation & Amortization | 28K | 286K | 2.07M | 2.4M | 2.35M | 2.4M | 2.34M | 1.7M | 1.7M | 2.85M |
| Stock-Based Compensation | 897K | 5.7M | 15.08M | 20.88M | 25.17M | 25.12M | 27.15M | 30.69M | 30.69M | 33M |
| Deferred Taxes | -197K | -978K | -3.16M | 4.36M | 11K | -185.5M | -33.79M | 8.13M | 8.13M | 9.66M |
| Other Non-Cash Items | -53K | -1.12M | 6.53M | 1.52M | 3.4M | 2.99M | 2.17M | 3.55M | -23.27M | 132.74M |
| Working Capital Changes | 13.93M | 18.33M | -17.02M | -4.32M | 689K | -22.57M | 1.35M | 24.81M | 51.63M | 16.74M |
| Change in Receivables | 0 | 0 | 0 | 0 | -3.91M | -16.33M | -950K | -20.46M | 26.13M | 16.84M |
| Change in Inventory | 0 | 0 | 0 | 0 | -3.67M | -17.92M | -9.52M | 4.76M | 4.76M | -51.07M |
| Change in Payables | 1.01M | 8.82M | -4.71M | -4.97M | 1.37M | 6.03M | 347K | -6.31M | -6.31M | 15.9M |
| Cash from Investing | -69K | -239.2M | 49.21M | -23.44M | 128.63M | -8.08M | -29.56M | 37.67M | 37.67M | -169.37M |
| Capital Expenditures | -69K | -5.29M | -3.2M | -283K | -415K | -105K | -130K | -277K | -277K | -339K |
| CapEx % of Revenue | - | - | - | - | 1.08% | 0.05% | 0.05% | 0.07% | 0.04% | - |
| Acquisitions | 0 | 0 | -52.42M | 23.16M | 0 | 0 | 0 | 25K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -233.91M | 52.42M | -23.16M | -20M | 91K | 0 | 0 | 25K | -226.64M |
| Cash from Financing | 39.87M | 346.74M | 84.11M | 227.09M | 5.88M | 2.52M | 1.5M | 12.27M | 12.27M | 36.33M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 39.87M | 350.02M | 83.11M | 228.22M | 0 | 3.42M | -2.21M | -4.98M | -7.73M | -7.32M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -2.21M | -4.98M | -7.73M | -7.32M |
| Other Financing | 0 | -3.28M | 1M | -1.14M | 5.88M | -901K | 3.7M | 17.25M | 20M | 43.65M |
| Net Change in Cash | -10.41M▲ 0% | 26.53M▲ 354.7% | -25.05M▼ 194.4% | 67.11M▲ 367.9% | 8.22M▼ 87.7% | 245K▼ 97.0% | -14.76M▼ 6124.9% | 75.63M▲ 612.3% | 75.63M▲ 0.0% | 32.82M▲ 0% |
| Free Cash Flow | -50.29M▲ 0% | -86.3M▼ 71.6% | -161.57M▼ 87.2% | -136.81M▲ 15.3% | -146.71M▼ 7.2% | 5.7M▲ 103.9% | 13.17M▲ 131.0% | 25.41M▲ 92.9% | 25.41M▲ 0.0% | 164.23M▲ 0% |
| FCF Margin % | - | - | - | - | -380.64% | 2.59% | 4.87% | 6% | 3.75% | 21.78% |
| FCF Growth % | -129.94% | -71.62% | -87.22% | 15.32% | -7.23% | 103.89% | 130.99% | 92.94% | 0% | 275.52% |
| FCF per Share | -1.55 | -2.92 | -2.99 | -2.21 | -2.14 | 0.08 | 0.18 | 0.36 | 0.32 | 0.32 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.78x | 0.98x | 0.85x | 0.80x | 0.03x | 0.94x | -0.59x | 0.44x | 2.25x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 290K | 383K | 1.72M | 482K | 1.28M | 10.69M | 5.61M | 2M | 0 | 1K |
KNSA Key Ratios
Kiniksa Pharmaceuticals, Ltd. (KNSA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -1037.68% | -60.06% | -63.55% | 63.1% | 3.37% | -9.85% | 11.73% | 13.26% |
| Return on Invested Capital (ROIC) | - | - | -70.37% | -61.15% | -85.91% | 4.21% | -6.07% | -11.26% | 17.13% | 17.13% |
| Gross Margin | - | - | - | - | 76.39% | 89.6% | 79.09% | 85.61% | 54.63% | 39% |
| Net Margin | - | - | - | - | -409.72% | 83.28% | 5.21% | -10.21% | 8.71% | 9.69% |
| Debt / Equity | - | - | 0.01x | 0.02x | 0.03x | 0.01x | 0.03x | 0.02x | 0.02x | 0.02x |
| FCF Conversion | 0.77x | 0.78x | 0.98x | 0.85x | 0.80x | 0.03x | 0.94x | -0.59x | 0.44x | 2.25x |
| Revenue Growth | - | - | - | - | - | 471.24% | 22.74% | 56.61% | 60.09% | 56.71% |
KNSA SEC Filings & Documents
Kiniksa Pharmaceuticals, Ltd. (KNSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
KNSA Frequently Asked Questions
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported $754.0M in revenue for fiscal year 2025.
Kiniksa Pharmaceuticals, Ltd. (KNSA) grew revenue by 60.1% over the past year. This is strong growth.
Yes, Kiniksa Pharmaceuticals, Ltd. (KNSA) is profitable, generating $73.1M in net income for fiscal year 2025 (8.7% net margin).
Dividend & Returns
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a return on equity (ROE) of 11.7%. This is reasonable for most industries.
Kiniksa Pharmaceuticals, Ltd. (KNSA) generated $164.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More KNSA
Kiniksa Pharmaceuticals, Ltd. (KNSA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates